AND EXCHANGE COMMISSION
TO SECTION 13 OR 15(D)
THE SECURITIES EXCHANGE ACT OF 1934
10, 2020 (February 10, 2020)
of Report (Date of earliest event reported)
name of registrant as specified in its charter)
|(State or other jurisdiction||
||(Commission File Number)||
Ludlow Avenue, Northvale, New Jersey 07647
of principal executive offices)
telephone number, including area code)
name or former address, if changed since last report.)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|☐||Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company ☐
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class
||Name of each exchange on which registered|
of Operations and Financial Condition.|
February 10, 2020, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) filed its quarterly report on Form
10-Q for the quarter ended December 31, 2019 and, thereafter, issued a press release announcing its financial results for that
quarter. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
noted in the press release, the Company will host a conference call at 11:00 AM Eastern Standard Time (EST) on Tuesday, February
11, 2020, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.
February 11, 2020|
questions by 7:00 AM EST on Tuesday, February 11, 2020. Email to: firstname.lastname@example.org |
||Regulation FD Disclosure.
information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report
on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,”
Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such,
the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section,
nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.
This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required
to be disclosed solely to satisfy the requirements of Regulation FD.
Statements and Exhibits.|
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
February 10, 2020
||ELITE PHARMACEUTICALS, INC.|
Hakim, President and CEO|